Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alligator Bioscience AB ( (SE:ATORX) ) has issued an announcement.
Alligator Bioscience AB has resolved a directed issue of 2,730,708 ordinary shares to guarantors following the exercise of warrants series TO 12, which had an exercise rate of approximately 71 percent. This move, along with a compensation issue of 1,182,876 shares, secures a capital injection of approximately SEK 10 million, reinforcing the company’s financial position and supporting its strategic focus on advancing mitazalimab towards a pivotal Phase 3 trial.
More about Alligator Bioscience AB
Alligator Bioscience AB is a company operating in the biotechnology industry, focusing on the development of innovative antibody-based immunotherapies. The company is particularly known for its work on mitazalimab, a promising candidate in their pipeline, and is actively engaged in advancing its clinical trials.
YTD Price Performance: -81.14%
Average Trading Volume: 244,328
Current Market Cap: SEK67.13M
See more data about ATORX stock on TipRanks’ Stock Analysis page.